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Summary The transcription factor, milk protein binding factor (MPBF/Stat5), is a member of the STAT
family of signalling molecules which mediates prolactin signal transduction in lactating mammary gland by
binding to GAS (y-interferon activation site) DNA elements. We have determined the levels of STAT factors
in nuclear extracts from a variety of human breast tissues including carcinoma and normal 'resting' breast by
electrophoretic mobility-shift assay. The results show that the level of STAT binding activity is low in normal
'resting' breast and benign lesions while carcinoma samples have significantly higher (P<O.OI) amounts of
STAT binding activity. Supershift analysis suggests that Statl and possibly other members of the STAT family
of signalling factors, including Stat3, are activated in breast cancer tissues.
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Growth and differentiation of the mammary gland is con-
trolled by a number of peptide and steriod hormones, includ-
ing epidermal growth factor (EGF) and prolactin (PRL)
(Topper and Freeman, 1980). In addition to its role in the
terminal differentiation of mammary epithelial cells, PRL is
involved also in the transcriptional regulation ofmilk protein
genes. The sheep P-lactoglobulin (BLG) milk protein gene
has been used as a model to allow the identification of
lactogenic hormone response elements and mammary trans-
cription factors which regulate BLG transcription (Watson et
al., 1991).
The proximal 400 bp of the BLG promoter has binding
sites for a number of transcription factors, including nuclear
factor 1 (NF1). In addition, the BLG promoter has three
binding sites, with different affinities, for a factor which is
present at high levels in the nuclei of cells from lactating
mammary gland from a number of species including mouse,
sheep and human (Watson et al., 1991). This factor, MPBF
(milk protein binding factor), binds to recognition sites in the
promoters of a number of other milk protein genes, including
P-casein, and is probably identical to MGF (mammary gland
factor, Schmitt-Ney et al., 1991). By mutating the three
MPBF binding sites in the BLG promoter and analysing the
effects of these mutations in both HC1 mammary cell cul-
ture and in the mammary glands of transgenic mice (Burdon
et al., 1994a), we have recently shown that MPBF is a
transcriptional activator of BLG and mediates the response
to lactogenic hormones. Furthermore, MPBF is induced by
PRL in HCII cells and in CHO cells stably transfected with
the long form of the PRL receptor (Burdon et al., 1994b,
Demmer et al., 1995).
The binding site for MPBF is closely related to the GAS
(interferon-y activation site) motif (Burdon et al., 1994b,
which is recognised by GAF, a factor induced in response to
interferon--y (IFN-'y) (Shuai et al., 1993). The receptors for
IFN-' and PRL are members of the cytokine/growth hor-
mone (GH) superfamily of receptors that lack intrinsic
tyrosine kinase activity (Bazan, 1990). Receptor-ligand bin-
ding activates specific members of the JAK kinase family,
which in turn phosphorylate STAT (signal transducer and
activator of transcription) transcription factors. Statl (p91) is
the binding component of GAF (Sadowski et al., 1993) and
is also activated in response to a number of cytokines and
growth factors. Recently, other factors which are related to
StatI have been cloned (reviewed by Darnell et al., 1994),
and these STAT factors, following phosphorylation on
tyrosine in response to receptor-ligand binding, become
translocated to the nucleus and bind to GAS recognition sites
in target promoters (Shuai et al., 1994). EGF treatment of
A431 cells induces three complexes which bind to the GAS
motifin the c-fos promoter (the serum-induced element, SIE),
and these complexes have been shown to consist of dimers of
Statl and/or Stat3 (Sadowski et al., 1993), which is identical
to the acute-phase response factor (APRF) (Akira et al.,
1994; Zhong et al., 1994). MPBF requires tyrosine phos-
phorylation for binding activity but is not antigenically
related to Statl, Stat2 (Burdon et al., 1994b) or Stat3 (CJ
Watson, unpublished observation). The recent molecular
cloning of sheep MGF shows that this factor is a novel
member of the Stat family (Wakao et al., 1994). MPBF/
MGF will subsequently be referred to as Stat5. All STAT
factors bind to similar GAS sites although specific sequence
requirements have not yet been determined.
In the mammary glands of mice and sheep, the level of
STAT-binding activity increases during gestational develop-
ment of the gland to reach maximal levels in early lactation.
During the proliferative phase of mammary development,
EGF has an essential role, suggesting that Statl and Stat3
may be activated at this stage of mammary development.
EGF and closely related growth factors also play a role in
the proliferation of breast cancer cells, specific receptors for
EGF and c-erbB-2 being overexpressed in a proportion of
breast tumours (Palk et al., 1990; Klijn et al., 1992). Further-
more, this phenotype of overexpression is associated with
poor prognosis (Sainsbury et al., 1987; Perren, 1991) and
resistance to treatment (Wright et al.,1992; Muss et al., 1994)
which suggests a functional influence on tumour behaviour.
It was therefore of interest to measure the amounts of STAT
factors in nuclear extracts derived from a variety of different
human breast tissues to determine whether differences in the
presence and amount of specific STAT factors exist between
breast tissue of differing pathologies.
Materials and methods
Breast tissue samples
Tissue samples from 51 patients undergoing surgery for a
variety of breast conditions were examined. Histological
examination of excised material confirmed 16 as carcinomas,
15 as fibroadenomas, eight as in situ carcinomas, three as
proliferating epithelial hyperplasias and three as other benign
lesions. Six specimens of breast tissue in which no obvious
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pathological abnormality could be detected histologically
(classified as normal resting breast) and one specimen of
normal lactating breast (from an accidental death) were also
studied. A mid-lactation sheep mammary gland sample was
also included as a control.
Nuclear extracts and electrophoretic mobility-shift assay
(EMSA)
Nuclear extracts were prepared by a modification of the
method of Dignam (1983) as previously described (Watson et
al., 1991). Briefly, breast samples (100 mg) were ground to a
fine powder under liquid nitrogen then dispersed in buffer
A/NT/L. The following manipulations were carried out at
4°C. The tissue was homogenised with a motor-driven
homogeniser to rupture cells and fibrous material was
removed by filtering through two layers of Miracloth. Nuclei
were collected by centrifugation in a Sorvall centrifuge at
2000 r.p.m. for 10 min. The pellet was washed in buffer
A/NT and recentrifuged to pellet the nuclei, which were then
lysed with lysis buffer and incubated with gentle shaking on
ice for 30 min. Chromosomal DNA and debris were removed
by centrifugation at 35000 r.p.m. for 30 min and the super-
natant dialysed for 4 h against 100 volumes of dialysis buffer
containing glycerol. Insoluble material was removed by brief
centrifugation and the cleared nuclear extract aliquoted and
flash frozen in liquid nitrogen. (EMSAs) were carried out as
previously described (Watson et al., 1991) using a 17 bp
double-stranded oligonucleotide (STM) which contained the
highest affinity binding sequence for StatS (GATTCCGG-
GAACCGCGT) and 4pg of nuclear extract. Complexes were
resolved on native 6% polyacrylamide gels which were fixed
and dried before quantitation and autoradiography.
Supershift analysis
Extracts were incubated with 1 j1l of the appropriate
antibody in bandshift buffer for 10 min at 25°C followed by
30 min at 4°C before the addition of radiolabelled STM
probe. Following incubation for 20 min at 25°C, complexes
were resolved on native polyacrylamide gels as above. Pro-
teins antigenically related to Statl or Stat3 were detected
with a polyclonal antibody to the amino-terminal 194 amino
acids of Statl (Transduction Laboratories) or an anti-Stat3
carboxy-terminal peptide antibody (a generous gift from Drs
Kishimoto and Akira, Osaka University; Akira et al., 1994)
respectively. Preimmune serum was used as a control.
gland. Equivalent amounts of protein from nuclear extracts
of each sample were used in an EMSA with the high-affinity
GAS site from the BLG promoter, STM, as probe. Each
specimen was analysed on at least four occasions and the
results of a typical assay in which all tissues were analysed
are shown in Figure 1. The Stat5 complexes detectable in the
lactating human and sheep mammary gland have different
mobilities, reflecting a difference in size between the bound
polypeptides in these species (Burdon et al., 1994b). Com-
plexes of similar mobility can be identified in the majority of
breast specimens analysed, although the incidence of detec-
tion and the amount of retarded probe varies widely between
the various histological subtypes. The highest incidence is
observed in invasive breast cancers, with 15 of 16 samples
showing marked binding activity; only one invasive car-
cinoma (lane 16) has an apparently undetectable level of
binding. Of the eight non-invasive in situ cancers, only three
possessed obvious binding activity and in only one case was
that substantial. Binding was low or undetectable in
fibroadenomas, with the exception of a single specimen (lane
40). Similarly, the amounts of retarded probe are low in
other benign specimens and normal resting breast.
Interestingly, a doublet is observed with a subset of the
carcinoma samples (lanes 3, 18 and 32). This is more clearly
seen in Figure 3. The different relative mobility of these
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Protein assay
Protein determinations were carried out with a commercial
kit (Pierce) and equivalent amounts of protein used for each
assay.
Quantitation andstatistical analysis
Retarded probe was quantitated using storage phosphor
fluorography with a Molecular Dynamics phosphorimager. A
track containing probe but no nuclear extract was quan-
titated to give background levels. The amount of STAT-
binding activity in each sample was determined in four
separate experiments. The results presented are from one
typical set of experiments carried out on the same day. The
results were always qualitativaly consistent, but absolute
amounts of retarded probe varied depending on the specific
activity of the probe.
Data were analysed statistically using analysis of variance
to estimate the difference between tissues and between gels.
Results-
Analysis ofSTAT-binding activity in breast tissue samples
In order to determine the levels of STAT-binding activity,
nuclear extracts were prepared from 51 breast samples, lac-
tating sheep mammary gland and lactating human mammary
Stat5
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Figure 1 STAT-binding activity in nuclear extracts from breast
samples. EMSA was carried out using 4 tg of protein from
nuclear extracts and labelled STM as probe. Complexes were
resolved on native PAGE gels and subject to autoradiography.
The category of tumour tissue is indicated above each lane. C,
Carcinoma; 1 in situ carcinoma; H, proliferating epithelial
hyperplasia; F, fibroadenoma; B, benign; R, normal resting
breast; L, lactating human breast; and S, lactating sheep mam-
mary gland. The position of the Stat5 complex is indicated and
the free probe is not shown.
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Figure 2 Quantitation of STAT-binding activity in relation to
tumour type. The amount of retarded probe in each complex was
quantitated using a phosphorimager and the results plotted for
each category of tumour. The mean value is indicated by a bar.
These results are plotted using arbitrary units of activity. Similar
results were obtained in four separate experiments.
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Figure 3 Supershift analysis of components of STAT complexes.
Nuclear extracts from breast samples or lactating human mam-
mary gland (4pg) were incubated with StatI or Stat3 specific
polyclonal antisera then radiolabelled STM oligonucleotide probe
added in a standard gel-shift assay. The source of extract and
addition of antibody are indicated above each lane; lactating
refers to lactating human mammary gland and the numbers refer
to the samples in Figure 1. Preimmune serum (pi) was used as
control. The positions of the Statl, Stat3 and Stat5 complexes are
indicated.
bands compared with the lactating complex suggests that
StatS may be present in different forms or that additional
STAT factors are found in carcinoma nuclear extracts. This
question is addressed below.
Quantitative analysis ofSTATfactors in breast tissues
The relative levels of STAT-binding activity in each sample
were determined by measuring the amount of retarded
radioactive probe in an EMSA. Four separate experiments
were carried out and similar results were obtained. Figure 2
shows the amount of retarded probe for each sample
categorised according to histological type in one typical
experiment. Statistical analysis of these results shows that the
carcinomas have significantly higher amounts of STAT-
binding activity (P<0.01) than all other samples (with the
exception of the lactating human and sheep mammary
glands) and that the differences between the other categories
of breast tissue are not statistically significant.
Human breast cancer samples contain nuclear Stati
In the EMSA analysis in Figure 1, the mobility of some of
the complexes is different from Stat5. For example, a more
slowly migrating complex is observed in lane 54 (carcinoma)
compared with the lactating breast complex (lane 55), and
doublets can be observed clearly on lower exposures of some
lanes (particularly 3, 18 and 32). This suggests that these
complexes have different constituents. This possibility was
addressed using an antibody supershift analysis. EMSA with
a variety of samples was performed in the usual way follow-
ing preincubation of extracts with antibodies to either Statl
or Stat3. Binding of antibody to the target STAT factor will
result in either the abolition of complex formation or an
alteration in the mobility of the antibody-bound STAT com-
plex (supershifting).
Figure 3 shows the results of a supershift analysis with two
invasive cancer samples, and one each of fibroadenoma, in
situ carcinoma, resting (normal breast) and lactating human
breast. StatS from lactating mammary gland is not composed
of either Statl or Stat3. We have previously also shown that
Stat2 is not a component of the lactating complex (Burdon et
al., 1994b). The binding activites in fibroadenoma number 40
and normal breast number 34 are also different from Statl
and Stat3. However, the lower band of the doublets in
carcinomas number 3 and 32 is supershifted by incubation
with the Statl antibody. This suggests that the lower band is
a homodimer of Statl or a heterodimer of Statl and another
Stat factor. The upper band appears to cross-react weakly
with the Stat3 antibody, indicating that Stat3 may be a
component of this complex. This would be consistent with
the lower apparent mobility of Stat3 compared with Statl
and Stat5. The complex observed with extract from in situ
number 42 is supershifted with the Statl antibody and is
likely to be composed of a homo- or heterodimer of Statl. In
EGF-treated A431 cell extracts, two complexes of similar
mobility to the cancer factors bind to the STM probe. The
faster migrating complex is supershifted with Statl antibody,
while incubation with the Stat3 antibody diminishes both
complexes (data not shown). These results show that a pro-
portion of breast cancers contain high levels of nuclear
STAT factors, and that the highest levels appear to be
associated with the presence of Statl.
Discussion
Results are presented which demonstrate that nuclear ext-
racts from invasive breast cancers display significantly higher
levels of STAT transcription factors than those from benign
and normal breast tissues, with the exception of lactating
breast. Thus 15 of 16 invasive cancers display evidence of
binding specifically to a high-affinity STAT factor recognition
motif. (The reason for the single invasive cancer not display-
ing activity is unclear; its histology was not of any particular
subtype and it displayed moderate cellularity without
evidence of necrosis or loss of cellular viability.) The
phenotype of enhanced factor-binding activity within breast
cancers seems to be a particular feature of invasive tumours
in that seven of eight in situ carcinomas possess substantially
lower activity, the values being lower than the mean for the
invasive group. (Again, the reason for the exceptional
tumour is not immediately apparent; the histology of a sec-
tion adjacent to that analysed for STAT binding was com-
patible with a non-invasive carcinoma although it cannot be
excluded that the material assayed did include foci of
invasion.) Normal and benign lesions showed low levels of
the STAT factors with the exception of certain
fibroadenomas. In particular, one fibroadenoma displayed
high levels of binding but, whereas supershift analysis
n} v~~ ~ .v _ , , _, w
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showed enhanced binding in cancers to be related to StatI
and possibly Stat3, the complex in the exceptional
fibroadenoma did not react with antibodies to either Statl or
Stat3 and was of the same mobility as StatS (the binding
activity in lactating breast).
The agents responsible for enhanced STAT binding
activity in breast tumours remain to be defined. Cancer cells
respond to a multitude of growth factors including EGF,
transforming growth factor alpha and beta, and insulin-like
growth factors (Lippman and Dickson, 1989). Furthermore,
a proportion of breast carcinomas overexpress EGF recep-
tors and as a result appear to be associated with poor
prognosis (Klijn et al., 1992, Sainsbury et al., 1987). The
EGF receptor is a member of the c-erbB family and it is
relevant that certain breast cancers may overexpress other
receptors within this family (Palk et al., 1990; Lemoine et al.,
1992). Activation of these receptors following binding with
their appropriate ligands involves events mediated by
tyrosine phosphorylation (Coussens et al., 1985), which may
ultimately programme for increased nuclear transcription via
the MAP kinase pathway and the STAT factors. Transfec-
tion of constitutively activated Ha-ras or v-raf, two down-
stream components of the EGF receptor signalling pathway,
into HCII mammary epithelial cells causes a block in the
lactogenic hormone induction of MGF (Stat5) and P-casein
(Happ et al., 1993). This is consistent with the observation
that EGF is antagonistic to the activation of StatS (Schmitt-
Ney et al., 1992) and may correlate with the observation of
high levels of Statl in invasive cancers. It will be interesting
to correlate the levels of EGF receptor and c-erbB-2 with the
presence of specific STAT factors in sections of breast
tumour samples.
The consequence ofincreased STAT factor-binding activity
in breast cancers is incompletely defined. Mammary tumour
cells from WAP-myc transgenic mice have been shown to
have hormone-independent Stat5 activity and constitutive P-
casein expression (Happ et al., 1993). However, it is possible
that the observed binding activity is a different STAT factor.
It is conceivable that elevated STAT activity will result in
continued transcriptional activation of specific genes other
than milk protein genes. For example, the promoter of the
c-fos gene has a GAS site (SIE) which binds StatI in vitro. If,
as is the case for c-fos, these genes are involved in regulating
proliferation, this will cause uncontrolled cell division.
Should this occur, it will be important to determine the
underlying reason for enhanced binding activity and the
mechanism by which it can be switched off. Certainly, a
greater understanding of these processes can only provide a
better understanding of tumour behaviour and may
ultimately lead to therapeutic meaasures for breast cancer
prevention and treatment.
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